AUG 20, 2018 08:35 AM PDT

Drug Seeks To Prevent a Painful Side-Effect

WRITTEN BY: Nouran Amin

Many patients with head, neck, nasal, and oral cancers are treated with radiations. Unfortunately, such treatment leaves patients with a painful side-effect known as severe oral mucositis (SOM). Even though there are drugs on the market that treat SOM, there isn’t yet anything effective to prevent it.

Now, researchers at the 256th National Meeting & Exposition of the American Chemical Society (ACS) have reported on a new drug referred to as ‘GC4419’ which may actually prevent SOM. Despite still being investigated in clinical trials, it is labeled as a “breakthrough therapy” by the U.S Food and Drug Administration. "It is exciting to publicly report on the structure and synthesis of GC4419 for the first time," says Dennis P. Riley, Ph.D., leader of the study. "We believe GC4419 has the potential to address an important unmet medical need in the treatment of cancer patients undergoing radiation therapy, and we look forward to commencing a Phase 3 trial with GC4419 in head and neck cancer patients this year."

 

Watch video below for a background overview on SOM:

 

Radiation therapy breaks down the epithelial lining on the insides of the mouth due to highly elevated superoxide radical levels which eventually causes the painful oral mucositis (OM) "The synthetic enzyme we designed and made mimics the function of the naturally occurring superoxide dismutase, an enzyme that converts superoxide to molecular oxygen and hydrogen peroxide," expalains Riley, who is with Galera Therapeutics. "Hydrogen peroxide is very toxic to cancer cells but not to normal cells. Thus, we create two opportunities to improve radiation therapy: reducing toxicity for normal cells while increasing the toxicity to the cancerous ones."

The research team faced many challenges in designing and creating a synthetic superoxide dismutase due to the complex molecular composition. "We had to figure out which isomer would work best and be the most 'druggable,'" reports Riley. "Our current synthesis involves using a template to make the 15-membered macrocylic ring complex in a single GMP [Good Manufacturing Practice] step. It uses pyridine-2,6- dicarboxyaldehyde, manganese(II) chloride and a linear tetramine synthesized from S,S-1,2 diaminocyclohexane. It is an elegantly simple 'one-pot' synthesis that yields the desired molecule with more than 99.5 percent chemical purity."

GC4419 has gone through successful completion of the Phase 1 and 2 clinical trials, which proved the safety and efficacy for SOM prevention in patients with head and neck cancer undergoing radiation therapy. Upon successful completions of the remaining phases in the trial, GC4418 will receive FDA approval.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 06, 2018
Drug Discovery
JUN 06, 2018
Computer Simulations Offer Alternative Methods for Diabetic Drugs
The Governor's Chair for Molecular Biophysics at the University of Tennessee (Knoxville), Jeremy Smith, and the director for the Center for Molecular B...
JUN 13, 2018
Drug Discovery
JUN 13, 2018
Small Molecule Seeks To Treat Asthma Attacks
For many individuals with asthma, a tiny particle almost invisible can trigger an asthmatic attack if it enters the airways of the respiratory system. Asth...
JUL 17, 2018
Drug Discovery
JUL 17, 2018
First Drug for Smallpox Treatment
TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox, was just approved by the U.S. Food and Drug Administration to SIGA Techno...
JUL 31, 2018
Drug Discovery
JUL 31, 2018
Pill Approved For Endometriosis Treatment
A first drug, by the name of Elagolix, to treat for endometriosis-related pain, has recently become approved by the US Food and Drug Administration. Endome...
SEP 04, 2018
Drug Discovery
SEP 04, 2018
Dopamine Provided Targeted Therapy for Neuropsychiatric Disorders
According to a study published in Molecular Psychiatry, research scientists at Columbia University Vagelos College of Physicians and Surgeons have brought ...
SEP 04, 2018
Drug Discovery
SEP 04, 2018
Treating Symptoms of Huntington Disease
According to a new study published in the Proceedings of the National Academy of Sciences (PNAS), a genetic disorder known as Huntington's disease may ...
Loading Comments...